Key facts
- It has raised $121.9M across 5 recorded rounds; the latest was Early Stage VC ($6.5M) in May 2025.
- Notable investors include United States Department of War, Keiretsu Forum, TEDCO, Angels + Life.Sci Investors Network, Astellas Pharma — 17 tracked in total.
- Immunomic Therapeutics has filed 6 Form Ds with the SEC since 2017, most recently Jun 2025 ($6.5M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Immunomic Therapeutics
Funding rounds
5 roundsAbout Immunomic Therapeutics
Developer of lysosomal-associated membrane protein (LAMP)-based vaccines designed to use immunotherapy to treat cancer, allergies, and animal health. The company's immunomodulation platform, LAMP-Vax, enables nucleic acid immunotherapy to utilize the body's natural biochemistry to develop an immune response, including antibody production, cytokine release, and critical immunological memory, enabling the healthcare industry to transform the rapidly growing allergy and cancer immunotherapy markets.
- Sector
- Healthcare
- HQ
- Rockville, MD, United States
- Founded
- 2005
- Employees
- 23
- Website
- immunomix.com/
- Ownership
- Privately Held (backing)
Immunomic Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Immunomic Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Immunomic Therapeutics in its N-PORT filings yet. We sweep new filings monthly.